Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Genetically modified mesenchymal stromal cells in cancer therapy.

Sage EK, Thakrar RM, Janes SM.

Cytotherapy. 2016 Nov;18(11):1435-1445. doi: 10.1016/j.jcyt.2016.09.003. Review.

3.

Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.

Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, Bueno R, Fennell DA, Broaddus VC.

PLoS One. 2016 Mar 16;11(3):e0150044. doi: 10.1371/journal.pone.0150044. eCollection 2016.

4.

Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.

Barbone D, Follo C, Echeverry N, Gerbaudo VH, Klabatsa A, Bueno R, Felley-Bosco E, Broaddus VC.

PLoS One. 2015 Aug 18;10(8):e0134825. doi: 10.1371/journal.pone.0134825. eCollection 2015.

5.

Apoptotic agents.

Fennell DA.

Transl Lung Cancer Res. 2013 Jun;2(3):238-43. doi: 10.3978/j.issn.2218-6751.2013.01.03. Review. No abstract available.

6.

Sialic acid-binding lectin (leczyme) induces apoptosis to malignant mesothelioma and exerts synergistic antitumor effects with TRAIL.

Tatsuta T, Hosono M, Takahashi K, Omoto T, Kariya Y, Sugawara S, Hakomori S, Nitta K.

Int J Oncol. 2014 Feb;44(2):377-84. doi: 10.3892/ijo.2013.2192. Epub 2013 Nov 28.

7.

Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.

Flusberg DA, Sorger PK.

Phys Biol. 2013 Jun;10(3):035002. doi: 10.1088/1478-3975/10/3/035002. Epub 2013 Jun 4.

8.

Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax.

Berger A, Quast SA, Plötz M, Kammermeier A, Eberle J.

Cell Death Dis. 2013 Jan 24;4:e477. doi: 10.1038/cddis.2012.198.

9.

Rejuvenating Bi(d)ology.

Zinkel SS, Yin XM, Gross A.

Oncogene. 2013 Jul 4;32(27):3213-9. doi: 10.1038/onc.2012.454. Epub 2012 Oct 15. Review.

10.

Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.

Du X, Xiang L, Mackall C, Pastan I.

Clin Cancer Res. 2011 Sep 15;17(18):5926-34. doi: 10.1158/1078-0432.CCR-11-1235. Epub 2011 Aug 3.

11.

Stem cells as vectors for antitumour therapy.

Loebinger MR, Janes SM.

Thorax. 2010 Apr;65(4):362-9. doi: 10.1136/thx.2009.128025. Review.

12.

Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers.

Peng X, Li Y, Walters KA, Rosenzweig ER, Lederer SL, Aicher LD, Proll S, Katze MG.

BMC Genomics. 2009 Aug 11;10:373. doi: 10.1186/1471-2164-10-373.

13.

BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.

Huang S, Okumura K, Sinicrope FA.

Clin Cancer Res. 2009 Jan 1;15(1):150-9. doi: 10.1158/1078-0432.CCR-08-1575.

14.

Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.

Yang TM, Barbone D, Fennell DA, Broaddus VC.

Am J Respir Cell Mol Biol. 2009 Jul;41(1):14-23. doi: 10.1165/rcmb.2008-0320OC. Epub 2008 Dec 18.

15.

IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.

Lesinski GB, Raig ET, Guenterberg K, Brown L, Go MR, Shah NN, Lewis A, Quimper M, Hade E, Young G, Chaudhury AR, Ladner KJ, Guttridge DC, Bouchard P, Carson WE 3rd.

Cancer Res. 2008 Oct 15;68(20):8351-60. doi: 10.1158/0008-5472.CAN-08-0426.

16.

BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.

Huang S, Sinicrope FA.

Cancer Res. 2008 Apr 15;68(8):2944-51. doi: 10.1158/0008-5472.CAN-07-2508.

17.

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.

Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC.

J Biol Chem. 2008 May 9;283(19):13021-30. doi: 10.1074/jbc.M709698200. Epub 2008 Mar 13.

18.

Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, Liu B.

Mol Cancer Ther. 2008 Mar;7(3):569-78. doi: 10.1158/1535-7163.MCT-07-2132. Epub 2008 Mar 4.

19.

CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes.

Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK, Boylan AM.

Am J Respir Cell Mol Biol. 2008 Jun;38(6):671-8. doi: 10.1165/rcmb.2007-0205OC. Epub 2008 Jan 24.

20.

A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.

Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC.

Am J Respir Cell Mol Biol. 2005 Dec;33(6):541-8. Epub 2005 Aug 25.

Supplemental Content

Support Center